Procès de Kanavape : Sébastien Béguerie la joue chanvre idéal Par Samantha Rouchard, correspondance à Marseille, — 22 octobre 2019 à 19:46 https://www.liberation.fr/france/2019/10/22/proces-de-kanavape-sebastien-beguerie-la-joue-chanvre-ideal_1759122 Après plus de quatre ans de feuilleton et une condamnation, la Cour de justice de l’UE se penche ce mercredi sur la vape au CBD conçue par le Marseillais, qui vante ses vertus relaxantes. La décision pourrait faire jurisprudence pour les dérivés de cannabis «light». «En lançant Kanavape, on se doutait qu’on allait faire un buzz mais pas de cette envergure !» Le Marseillais Sébastien Béguerie est l’inventeur de la première cigarette électronique au cannabidiol (CBD), molécule du cannabis dite relaxante, au statut juridique toujours indéterminé en France. Son lancement [...]
Lire la suiteCannabis : un secteur enfumé par les autorités Par Charles Delouche — 22 octobre 2019 à 19:46 Libération https://www.liberation.fr/france/2019/10/22/cannabis-un-secteur-enfume-par-les-autorites_1759124 L’Organisation mondiale de la santé a beau estimer que le CBD n’est ni nocif ni addictif, la France campe sur ses positions et continue de pénaliser toute commercialisation. Garanti sans effet psychotrope mais pas sans flou juridique. Molécule de chanvre présente dans le cannabis, le cannabidiol (CBD) fait l’objet depuis l’été 2018 d’une attention particulière de la part des consommateurs comme des services de police. Cosmétiques, e-liquides, sucreries, baumes, huiles : moult boutiques spécialisées dans les produits au CBD ont vu le jour en France. Découverte en 1940, [...]
Lire la suiteCannabis : fumée blanche pour idées vertes à l'Assemblée Par Charles Delouche — 11 juillet 2019 à 19:51 Liberation https://www.liberation.fr/france/2019/07/11/cannabis-fumee-blanche-pour-idees-vertes-a-l-assemblee_1739459 Alors que l'Agence nationale de sécurité du médicament vient de valider le cadre d'expérimentation retenu pour le cannabis médical, une mission d'information parlementaire sur les différents usages du cannabis a été lancée dans la foulée. Battre le fer tant qu’il est chaud. C’est l’adage retenu par les parlementaires à l’initiative de la mission d’information sur les différents usages du cannabis. Réunis à l’Assemblée nationale pour un colloque autour du «chanvre bien-être» et ses produits garantis sans psychotropes, parlementaires [...]
Lire la suiteEvaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients : a prospective cohort study Alex Capano, Richard Weaver & Elisa Burkman Postgraduate Medicine, 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Doi : 10.1080/00325481.2019.1685298 ABSTRACT Context : Chronic pain is highly prevalent in most of the industrialized nations around the world. Despite the documented adverse effects, opioids are widely used for pain management. Cannabinoids, and specifically Cannabidiol, is proposed as an opioid alternative, having comparable efficacy with better safety profile. Objectives : We aim to investigate the impact [...]
Lire la suiteTwo-thirds of Americans support marijuana legalization By Andrew Daniller Pew Research Center, FactTank, November 14, 2019 https://www.pewresearch.org/fact-tank/2019/11/14/americans-support-marijuana-legalization/?utm_source=AdaptiveMailer&utm_medium=email&utm_campaign=19-11-07%20Marijuana%20Legalization%20Heads-up&org=982&lvl=100&ite=4914&lea=1115963&ctr=0&par=1&trk= Two-thirds of Americans say the use of marijuana should be legal, reflecting a steady increase over the past decade, according to a new Pew Research Center survey. The share of U.S. adults who oppose legalization has fallen from 52% in 2010 to 32% today. Meanwhile, an overwhelming majority of U.S. adults (91%) say marijuana should be legal either for medical and recreational use (59%) or that it should be legal just for medical use (32%). Fewer than one-in-ten (8%) prefer to keep marijuana illegal in all circumstances, according [...]
Lire la suiteMedical cannabis trial will target 20,000 UK patients Jamie Doward and Lily Gordon Brown The GUARDIAN, Published on Sun 3 Nov 2019 https://www.theguardian.com/society/2019/nov/03/medical-cannabis-uk-clinical-trial-patients-nhs Project backed by Royal College of Psychiatrists aims to be largest on drug’s use in Europe • Medical cannabis: Why are doctors still not prescribing it? Tilray medicinal cannabis growing facility in Canada. Photograph: Tilray Up to 20,000 patients in the UK are to be given medical cannabis over a two-year period in an initiative that aims to create the largest body of evidence on the drug in Europe. The move, to be unveiled on Thursday, is [...]
Lire la suiteMedicinal Cannabis on Prescription in The Netherlands : Statistics for 2003–2016 Bas de Hoop, Eibert R. Heerdink, and Arno Hazekamp Cannabis and Cannabinoid Research, 2018, Volume 3.1, Doi : 10.1089/can.2017.0059 In 2003, the Netherlands started one of the first National medicinal cannabis programs in the world, where patients are provided with pharmaceutical-grade cannabis of standardized cannabinoid composition. The program is overseen by the Office of Medicinal Cannabis (OMC), which is part of the Ministry of Health, while cultivation, packaging, lab testing, and distribution are performed by contracted specialized companies. Medicinal cannabis is available on prescription only and can be dispensed by all Dutch pharmacies. [...]
Lire la suiteMyorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD : A Randomized, Double-Blind Trial Aleksandra Nitecka-Buchta, Anna Nowak-Wachol, KacperWachol, KarolinaWalczynska-Dragon, Paweł Olczyk, Olgierd Batoryna, Wojciech Kempa and Stefan Baron Journal of Clinical Medicine, 2019, 8, 188, 1-17. doi : 10.3390/jcm8111886 Abstract Background : The healing properties of cannabidiol (CBD) have been known for centuries. In this study, we aimed to evaluate the efficiency of the myorelaxant effect of CBD after the transdermal application in patients with myofascial pain. Methods : The Polish version of the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD Ia and Ib) was used. A total of 60 patients were enrolled [...]
Lire la suiteEffects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use Paulo Fleury-Teixeira, Fabio Viegas Caixeta, Leandro Cruz Ramires da Silva, Joaquim Pereira Brasil-Neto and Renato Malcher-Lopes Frontiers in Neurology, October 2019, Volume 10, Article 1145 doi : 10.3389/fneur.2019.01145 Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and [...]
Lire la suiteStudy protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease progression of Amyotrophic Lateral sclerosis or motor neurone Disease : the EMERALD trial Berzenn Urbi, Simon Broadley, Richard Bedlack, Ethan Russo, Arman Sabet British Medical Journal Open, 2019, 9, e029449. doi : 10.1136/bmjopen-2019-029449 Abstract Introduction : Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure and with an average life expectancy of 3–5 years post diagnosis. The use of complementary medicine such as medicinal cannabis in search for a potential treatment or cure is common in ALS. Preclinical studies have demonstrated the efficacy [...]
Lire la suite